10/6/2011

The Defense Department has awarded Entegrion a $43.7 million contract to further develop the biotech company's Resusix plasma product. The technology, which the company says provides a better alternative to frozen blood plasma, would enable military staffers to dry and store plasma that they could use in combat situations.

Related Summaries